摘要
目的探讨阿托伐他汀钙、依那普利联合缬沙坦治疗高血压肾病的效果及对患者肾功能及炎症因子指标水平的影响。方法选取2017年12月至2020年5月我院收治的106例高血压肾病患者作为研究对象,将其随机分为对照组(53例,依那普利联合缬沙坦治疗)与观察组(53例,阿托伐他汀钙、依那普利联合缬沙坦治疗)。比较两组治疗前、后的血压、肾功能指标、炎症因子指标及生活质量。结果治疗后,两组的收缩压及舒张压均有所降低,且观察组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组的Scr、BUN水平及24 h尿蛋白定量均降低,且观察组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组的TNF-α、IL-6及CRP水平均有所降低,且观察组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组的躯体症状、社会功能障碍、焦虑/失眠及严重压抑评分均有所降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。结论阿托伐他汀钙、依那普利联合缬沙坦治疗高血压肾病的效果显著,其可降低患者的血压,减轻机体的炎症反应,提高肾功能及生活质量,值得推广。
Objective To investigate the effects of atorvastatin calcium and enalapril combined with valsartan in the treatment of hypertensive nephropathy and its influences on renal function and inflammatory factors indexes levels of patients.Methods A total of 106 patients with hypertension nephropathy treated in our hospital from December 2017 to May 2020 were selected as the study objects and randomly divided into control group(53 cases,enalapril combined with valsartan)and observation group(53 cases,atorvastatin calcium,enalapril combined with valsartan).The blood pressure,renal function indexes,inflammatory factor indexes and living quality of the two groups before and after treatment were compared.Results After treatment,the systolic and diastolic blood pressure of the two groups decreased,and those of the observation group were lower than the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of Scr,BUN and 24 h urinary protein quantitation in both groups decreased,and those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of TNF-α,IL-6,CRP in both groups decreased,and those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05);after treatment,the scores of somatic symptoms,social dysfunction,anxiety/insomnia and severe depression in both groups decreased,and those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).Conclusion Atorvastatin calcium,enalapril combined with valsartan in the treatment of hypertensive nephropathy have a significant effect,it can reduce patients'blood pressure,alleviate the body's inflammatory response,improve renal function and quality of life,which is worthy of promotion.
作者
张娓娓
雷银虎
ZHANG Weiwei;LEI Yinhu(Ankang Central Hospital,Ankang 725000;Dongfeng Central Health Center of Long County,Baoji 721200,China)
出处
《临床医学研究与实践》
2021年第34期60-62,共3页
Clinical Research and Practice
关键词
阿托伐他汀钙
依那普利
缬沙坦
高血压肾病
atorvastatin calcium
enalapril
valsartan
hypertensive nephropathy
